Abstract 187P
Background
Chemoradiation in Stomach is indicated in patients who do not receive perioperative chemotherapy. While contouring the organs at risk in CRT of stomach spleen is not considered as the organ at risk (OARS). Leukopenia is also seen very commonly during the CRT of stomach. We are trying to correlate the grade of leukopenia to the dose received by spleen during CRT of stomach. The primary aim of this study -To determine the dose achieved by Spleen during the Post Operative Adjuvant Radiotherapy of Carcinoma Stomach. Correlate the dose achieved to the weekly blood counts (Grade 3 Hematological Toxicity).
Methods
Patients attending Kasturba Medical College OPD diagnosed with Carcinoma Stomach and planned for Adjuvant Chemoradiation were considered for the study. We analyzed 42 patients from the Jan 2018 to December 2018. The Dosimetric and Volumetric Parameters were calculated for Spleen. The patients in our study underwent Upfront Gastrectomy (Total/Partial) and received 2 cycles of Adjuvant Chemotherapy (CAPOX). Then referred for adjuvant Chemoradiation.
Results
The Mean dose achieved was 36 Gy. The range of dose received by the spleen ranged from 35Gy- 45 Gy. The doses were high when splenic nodes were irradiated. 18 patients (42%) presented with Grade 3 Hematological toxicity( Leukopenia). 15 patients (35%) could not receive Concurrent Chemotherapy in view of non recovery of Hematological Toxicities.
Conclusions
From our study we found that Spleen is a Dose limiting Structure while planning the Adjuvant Post Operative Radiotherapy in Carcinoma Stomach. The dose received by spleen can be correlated with the grade of Leukopenia in patients receiving adjuvant CRT for Carcinoma Stomach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr Umesh Velu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract